



Product Information

Product ID A9435

CAS No. 319460-85-0

Chemical Name N-methyl-2-[[3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl]sulfanyl]benzamide

Synonym

Formula C₂₂H₁₈N₄OS

Formula Wt. 386.47

Melting Point 213-224 °C


Purity ≥98%

Solubility

Store Temp Ambient

Ship Temp Ambient

Description Axitinib is an inhibitor of VEGFR that exhibits anticancer chemotherapeutic and anti-angiogenic activities. Axitinib is currently in clinical trials as a potential treatment for renal cell carcinoma. In vitro, axitinib increases levels of CD8+ T cells and decreases levels of myeloid-derived suppressor cells, inhibiting proliferation and increasing apoptosis. In vivo, this compound inhibits expression of iNOS, arginase, IL-6, TNF-α, and IFN-γ, increasing apoptosis and inhibiting tumor growth. In animal models of lung adenocarcinoma, axitinib decreases tumor vasculature and lesion growth.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A9435	5 mg	\$52.50
A9435	25 mg	\$112.60
A9435	100 mg	\$188.00

References Zhang X, Fang X, Gao Z, et al. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. *Anticancer Drugs*. 2014 Feb;25(2):204-11. PMID: 24135499.

Gross-Goupil M, François L, Quivy A, et al. Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma. *Clin Med Insights Oncol*. 2013 Oct 29;7:269-277. PMID: 24250243.

Majeti BK, Lee JH, Simmons BH, et al. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. *BMC Cancer*. 2013 Apr 29;13(1):213. [Epub ahead of print]. PMID: 23627488.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.